Yasuhiro Ohara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasuhiro Ohara has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Masakazu Doshida
Department of Reproductive Medicine Reproduction Clinic Tokyo Tokyo Japan
4 shared publicationsHidehiko Matsubayashi
Department of Reproductive Medicine Reproduction Clinic Osaka Osaka Japan
3 shared publicationsTakumi Takeuchi
Department of Reproductive Medicine Reproduction Clinic Tokyo Tokyo Japan
3 shared publicationsTomomoto Ishikawa
Department of Reproductive Medicine Reproduction Clinic Osaka Osaka Japan
3 shared publications- Mai Nishimura
Public Interest Incorporated Foundation Japanese Foundation for Cancer Research, Department of Gynecologic Oncology, Cancer Institute Hospital, Tokyo, Japan
2 shared publications Mika Handa
Department of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 25 (1) , e70081
Personalized Embryo Transfer Improves Live Birth Rates in Recurrent Implantation Failure: A Propensity Score‐Matched Prospective Cohort Study With Window of Implantation Stability Analysis
Purpose: To evaluate the clinical efficacy of ERPeak SM ‐guided personalized embryo transfer (pET) in recurrent implantation failure (RIF) and non‐RIF patients, and assess the temporal stability of the window of implantation (WOI). Methods: This prospective cohort study included patients undergoing frozen embryo transfer (FET) with good‐quality embryos. In hormone replacement therapy (HRT) cycles, RIF patients received pET ( n = 199) or non‐personalized ET (npET, n = 272); non‐RIF patients received pET ( n = 74) or npET ( n = 351). Propensity score matching (PSM) adjusted for confounders. modified Natural cycle (mNC) FET was analyzed using inverse probability of treatment weighting (IPTW). WOI stability was evaluated via Kaplan–Meier analysis. Results: Following PSM in RIF patients, pET significantly improved live birth rates (LBR) compared to npET (41.0% vs. 23.6%, p < 0.001) and reduced miscarriage rates (17.4% vs. 36.2%, p = 0.014). In non‐RIF patients, pET did not improve LBR (35.8% vs. 25.4%, p = 0.26). IPTW‐adjusted mNC‐FET analysis showed significantly higher LBR in the pET group (46.3% vs. 19.2%, p = 0.026). Kaplan–Meier analysis revealed WOI stability declines significantly faster in patients ≥ 38 years (median 30.0 months, p = 0.0059). Conclusions: ERPeak SM ‐guided pET significantly improves LBR in RIF patients undergoing HRT and mNC‐FET, but lacks benefit in non‐RIF patients. WOI is dynamic; reevaluation is recommended for older patients.
- 1 January 2026
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 25 (1) , e70081
Open AccessPersonalized Embryo Transfer Improves Live Birth Rates in Recurrent Implantation Failure: A Propensity Score‐Matched Prospective Cohort Study With Window of Implantation Stability Analysis
Purpose: To evaluate the clinical efficacy of ERPeak SM ‐guided personalized embryo transfer (pET) in recurrent implantation failure (RIF) and non‐RIF patients, and assess the temporal stability of the window of implantation (WOI). Methods: This prospective cohort study included patients undergoing frozen embryo transfer (FET) with good‐quality embryos. In hormone replacement therapy (HRT) cycles, RIF patients received pET ( n = 199) or non‐personalized ET (npET, n = 272); non‐RIF patients received pET ( n = 74) or npET ( n = 351). Propensity score matching (PSM) adjusted for confounders. modified Natural cycle (mNC) FET was analyzed using inverse probability of treatment weighting (IPTW). WOI stability was evaluated via Kaplan–Meier analysis. Results: Following PSM in RIF patients, pET significantly improved live birth rates (LBR) compared to npET (41.0% vs. 23.6%, p < 0.001) and reduced miscarriage rates (17.4% vs. 36.2%, p = 0.014). In non‐RIF patients, pET did not improve LBR (35.8% vs. 25.4%, p = 0.26). IPTW‐adjusted mNC‐FET analysis showed significantly higher LBR in the pET group (46.3% vs. 19.2%, p = 0.026). Kaplan–Meier analysis revealed WOI stability declines significantly faster in patients ≥ 38 years (median 30.0 months, p = 0.0059). Conclusions: ERPeak SM ‐guided pET significantly improves LBR in RIF patients undergoing HRT and mNC‐FET, but lacks benefit in non‐RIF patients. WOI is dynamic; reevaluation is recommended for older patients.
- 23 August 2024
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 50 (2) , 104405
Tailor-made embryo transfer considering embryonic developmental speed to overcome the dilemma of personalized embryo transfer
- 23 August 2024
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 50 (2) , 104405
Tailor-made embryo transfer considering embryonic developmental speed to overcome the dilemma of personalized embryo transfer
- Open Access
- 1 January 2022
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 21 (1) , e12444
Clinical relevance of a newly developed endometrial receptivity test for patients with recurrent implantation failure in Japan
Purpose: To assess the clinical efficacy of personalized embryo transfer (pET) guided by a new endometrial receptivity test, ERPeakSM, in patients with recurrent implantation failure (RIF).Methods: Recurrent implantation failure patients of all ages at two private Japanese clinics from April 2019 to June 2020 were retrospectively analyzed. The intervention group (n = 244) received pET in accordance with endometrial receptivity testing results and was compared to control group (n = 306) receiving standardized timing, non‐personalized embryo transfer (npET). In propensity score matching analysis, the clinical pregnancy rate (CPR) and live birth rate (LBR) were compared between groups, and a subanalysis of advanced maternal age (AMA) (≥38 years old) versus non‐AMA (p < 0.001 and 29.9% vs. 9.7%, adjusted OR: 4.13; 95%CI, 2.40–7.13, p < 0.001, respectively). Furthermore, in the subanalyses, the CPR and LBR of the pET group were significantly higher than those of the npET group in both the AMA non‐AMA patients.Conclusions: The new ERPeakSM endometrial receptivity test is a useful alternative diagnostic tool for poor‐prognosis patients, regardless of age.
- 1 January 2022
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 21 (1) , e12444
Open AccessClinical relevance of a newly developed endometrial receptivity test for patients with recurrent implantation failure in Japan
Purpose: To assess the clinical efficacy of personalized embryo transfer (pET) guided by a new endometrial receptivity test, ERPeakSM, in patients with recurrent implantation failure (RIF).Methods: Recurrent implantation failure patients of all ages at two private Japanese clinics from April 2019 to June 2020 were retrospectively analyzed. The intervention group (n = 244) received pET in accordance with endometrial receptivity testing results and was compared to control group (n = 306) receiving standardized timing, non‐personalized embryo transfer (npET). In propensity score matching analysis, the clinical pregnancy rate (CPR) and live birth rate (LBR) were compared between groups, and a subanalysis of advanced maternal age (AMA) (≥38 years old) versus non‐AMA (p < 0.001 and 29.9% vs. 9.7%, adjusted OR: 4.13; 95%CI, 2.40–7.13, p < 0.001, respectively). Furthermore, in the subanalyses, the CPR and LBR of the pET group were significantly higher than those of the npET group in both the AMA non‐AMA patients.Conclusions: The new ERPeakSM endometrial receptivity test is a useful alternative diagnostic tool for poor‐prognosis patients, regardless of age.
- 1 September 2021
- Published by Elsevier in Fertility and Sterility
- Vol. 116 (3) , e314-e315
CLINICAL UTILITY OF THE NEW ENDOMETRIAL RECEPTIVITY TEST IN ADVANCED MATERNAL AGE PATIENTS WITH RECURRENT IMPLANTATION FAILURE
- 1 September 2021
- Published by Elsevier in Fertility and Sterility
- Vol. 116 (3) , e314-e315
CLINICAL UTILITY OF THE NEW ENDOMETRIAL RECEPTIVITY TEST IN ADVANCED MATERNAL AGE PATIENTS WITH RECURRENT IMPLANTATION FAILURE
- 1 April 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (4) , 101735
Combination of conservative treatment and temporary bilateral laparoscopic uterine artery clipping with hysteroscopic transcervical resection for cervical pregnancy: A retrospective study
- 1 April 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (4) , 101735
Combination of conservative treatment and temporary bilateral laparoscopic uterine artery clipping with hysteroscopic transcervical resection for cervical pregnancy: A retrospective study
- 1 July 2019
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 26 (5) , 798-799
Laparoscopic Management of Cesarean Scar Pregnancy
- 1 July 2019
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 26 (5) , 798-799
Laparoscopic Management of Cesarean Scar Pregnancy
- Open Access
- 1 January 2018
- Published by Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy in JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
- Vol. 34 (1) , 128-133
Laparoscopic surgery in osteogenesis imperfecta (OI) patient with tubo-ovarian abscess (TOA): A case report
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。
- 1 January 2018
- Published by Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy in JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
- Vol. 34 (1) , 128-133
Open AccessLaparoscopic surgery in osteogenesis imperfecta (OI) patient with tubo-ovarian abscess (TOA): A case report
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。